News

Key Stats for Amgen StockCurrent Price: $375. 65Target Price (Mid): ~$495Street Target: ~$388Potential Total Return: ~32%Annualized IRR: ~6.

Barclays analyst Glen Santangelo raised the stock to Overweight from Underweight and lifted his target to $8 from $4.

The biotech company’s stock rises after Barclays gives it a double upgrade, citing confidence in upcoming FDA approvals.

Eli Lilly (LLY) trades near $1,120, about 13% below the high it set in August, and the question is whether to step in. The stock's record after sharp falls is clean but short. That record asks for the better part of a year and more pain before it pays. And this fall is not the kind of fall that record is built on.

Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.

Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.

One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.

Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.

The Imdelltra-Imfinzi combination improved survival and response measures in a 563-patient late-stage lung-cancer trial.

Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.

Wall Street returns from summer vacation to a market suddenly bracing for a rate hike, with fresh analyst calls on Intel, Lockheed Martin, Amgen, and SpaceX adding more pressure points to an already tense week.

Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

Gilead Sciences has rallied the S&P 500 Index over the past year, and analysts remain highly bullish about the stock’s growth prospects.

Impressive results came out on drugs from Amgen, Arrowhead Pharmaceuticals, and Crispr Therapeutics. Their shares are all lower this week.

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

Stock Market Today: The Dow Jones index falls, but tech futures rally Thursday as Nvidia, Salesforce and CrowdStrike surge on earnings.

Amgen (NasdaqGS:AMGN) has elected to terminate its research collaboration and license agreement with TScan Therapeutics focused on Crohn's disease target discovery. The decision ends Amgen's exclusive effort with TScan to identify and develop T-cell antigen targets for Crohn's disease. This change may affect Amgen's research pipeline in inflammatory bowel disease and influence its future approach to biotech partnerships. For broader context on the sector, consider exploring other...

Three catalysts, one reshuffling, and a Fed that refuses to move

AMGN, FCFS and DK delivered strong gains, highlighting Zacks research successes across several model portfolios.

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

Suddenly the Nasdaq couldn’t hold onto early gains, and you can probably guess which stocks are to blame. The Nasdaq Composite was hovering around breakeven after a wave of selling hit chips and AI infrastructure stocks. The S&P 500 was still up 0.3%.

Investors rotated toward profitable drugmakers while personalized cancer-vaccine results energized biotechnology stocks.

They are way more than just GLP-1 stocks.

Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic inside the BofA research note on biotech I received on the ...

BeOne Medicines Ltd (ONC) delivers robust Q2 2026 results with record BRUKINSA sales, raises full-year guidance, and advances a promising oncology pipeline.

Amgen is back in focus after updated valuation work lifted its modeled fair value from US$352.23 to US$371.93 per share, signaling a higher price target in the latest analyst run. Much of Wall Street commentary around this shift ties to recent Q2 beats, raised guidance, and differing views on how durable the current growth and pipeline story really is. As you read on, you will see how these moving pieces shape the evolving Amgen narrative and what to watch next in the research. Stay updated...

Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market.

Rapid growth across cardiovascular, bone and rare-disease medicines allowed Amgen to raise guidance despite abandoning an obesity candidate.

Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.